Pfizer (PFE) Minority Interest (2009 - 2026)

Pfizer (PFE) has reported Minority Interest for 18 consecutive years, with $302.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Minority Interest fell 4.73% year-over-year to $302.0 million in Q2 2026; TTM through Jun 2026 was $302.0 million, a 4.73% decrease from a year earlier, with the FY2025 full-year figure at $299.0 million, up 1.7% from the prior year.
• Minority Interest was $302.0 million for Q2 2026 at Pfizer, roughly flat from $303.0 million in the prior quarter.
• Over five years, Minority Interest peaked at $317.0 million in Q2 2025 and troughed at $227.0 million in Q3 2022.
• A 5-year average of $277.8 million and a median of $274.5 million in 2023 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest declined 17.45% in 2022 and advanced 15.27% in 2025, its largest moves.
• Over 5 years, Minority Interest stood at $256.0 million in 2022, then grew by 7.03% to $274.0 million in 2023, then rose by 7.3% to $294.0 million in 2024, then gained by 1.7% to $299.0 million in 2025, then grew by 1.0% to $302.0 million in 2026.
• The last three Minority Interest figures came in at $302.0 million (Q2 2026), $303.0 million (Q1 2026), and $299.0 million (Q4 2025), per Business Quant data.